
Navigating Fertility and Family Planning in Melanoma and Skin Cancer
TBD
Navigating fertility and family planning can be a complex journey, especially for those diagnosed with melanoma or skin cancer. This webpage aims to provide insights and support for individuals and couples facing these challenges.
Join Dr. Joël Claveau as he delves into the complexities of targeted therapy and immunotherapy. These treatments, known for their effectiveness, also come with potential side effects, especially dermatological reactions.
​
-
Dermatological Reactions: Insight into skin, hair, nails, and eye reactions associated with immunotherapy.
-
Incidence and Onset of cirAEs: Variability based on drug class, type of cancer, and patient-related factors.
-
Common cirAEs: Frequent occurrences include pruritus, lichen planus, psoriasiform reactions, eczematoid eruptions, morbilliform eruptions, and bullous diseases.
-
Therapeutic Response Indications: Certain cirAEs may indicate a positive therapeutic response and predict survival outcomes.
Webinar:
Understanding Cutaneous Reactions in Advanced Cancer Treatments
Proactive Measures
Rash Prevention:
-
Assess for pre-existing conditions (e.g., psoriasis, acne vulgaris, rosacea)
-
Encourage hydration
-
Use alcohol-free emollients
-
Apply broad-spectrum sunscreen (UVA, UVB)
Dry Skin and Fissure Care:
-
Use tepid water
-
Use mild soaps and bath oils
-
Apply moisturizers several times a day
-
Wear protective footwear
-
Avoid hot water, frequent bathing, and alcohol-containing lotions
Management of Severe Reactions:
-
Ensure skin toxicity is not life-threatening
-
Manage with topical and systemic steroids if necessary
-
Sometimes temporarily interrupt immunotherapy
Management
Dr. Joel Claveau’s Approach:
-
Preventative Dermocosmetic Regime:
-
Hygiene + moisturizer + sun protection + camouflage
-
-
Treatment Modalities:
-
Radiation
-
Chemotherapy
-
Targeted therapy
-
Immunotherapy
-
Hormonal therapy
-
Surgery
-
Transplant
-
CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors:
A Practical Primer
​
The CaSMO advisors created a practical guide on the prevention, identification, and treatment of cirAEs, with a focus on skincare for conditions like isolated pruritus, psoriasiform eruptions, lichenoid eruptions, eczematous eruptions, and bullous pemphigoid. The development of this guide followed a modified Delphi approach. The recommendations provided by the CaSMO advisors are informed by guidelines, algorithms, consensus papers, and systematic reviews, as well as their clinical experience and discussions.

References
Dr. Joël Claveau, Diplomate of the American Board of Dermatology, Fellow of the Royal College of Physicians of Canada, Associate Professor, Department of Medicine, Laval University, Director of Melanoma and Skin Clinic, Le Centre Hospitalier Universitaire de Québec, Hôtel-Dieu de Québec, Quebec City, QC, Canada. Dr. Maxwell B. Sauder, Onco-dermatologist, Princess Margaret Cancer Centre, Director, Toronto, ON, Canada. Dr. Charles W. Lynde, Fellow of the Royal College of Physicians of Canada, Diplomate of the American Board of Dermatology, Associate Professor, Department of Medicine, University of Toronto, Toronto, ON, Canada, Lynderm Research, Markham, ON, Canada. Dr. Anneke Andriessen, Radboud UMC, Nijmegen and Andriessen Consultants, Malden, The Netherlands. Dr. Tarek Hijal, Fellow of the Royal College of Physicians of Canada, Associate Professor, Department of Oncology, McGill University; Director, Division of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada. Dr. Nicole M. C. Clemens, Medical Oncologist, Medical Oncology Disease Site Lead for Melanoma/Skin Oncology, Princess Margaret Cancer Centre. Assistant Professor, Department of Medicine, University of Toronto, Associate Member, Department of Immunology, University of Toronto, Toronto, ON, Canada. Lacouture ME, et al. Support Care Cancer. 2011;19(8):1079-95. Robert C, et al. Lancet Oncology 2015;16(4):e181-9. Canadian Skin Management in Oncology (CaSMO)